E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of condyloma acuminata and anal cancers and related precancers caused by Human Papillomavirus (HPV) 6, 11, 16 and 18 |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of HPV related cancers in men |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071147 |
E.1.2 | Term | Human papilloma virus immunization |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
(1) To demonstrate that administration of V501 induces high seroconversion rates for the vaccine HPV types (6, 11, 16 and 18) at 4 weeks post dose 3 in 9- to 15-year-old Japanese boys.
(2) To demonstrate that a 3-dose regimen of V501 to 9- to 15-year-old Japanese boys is well tolerated.
|
|
E.2.2 | Secondary objectives of the trial |
(1) To demonstrate that administration of V501 induces non-inferior geometric mean titers (GMTs) for serum anti-HPV 6, 11, 16 and 18 at 4 weeks post dose 3 in Japanese boys aged 9- to 15-year-old compared with those in Japanese men aged 16- to 26-year-old in Phase III study (Protocol 122) for V501 at 4 weeks post dose 3.
(2) To describe the persistence of the serum antibody titers for the vaccine HPV types 24 months following the third dose of V501.
(3) To estimate the immune response for the vaccine HPV types (6, 11, 16 and 18) at 4 weeks post dose 3 using GMTs.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose
of the correct drug at the correct time. |
|
E.3 | Principal inclusion criteria |
1. Be a healthy, Japanese male between the age of 9 years and 0 days and 15 years and 364 days on the day of the first study vaccination.
2. Have a legal representative who provides written informed consent for the trial on the subject’s behalf. The legal representative may also provide consent for Future Biomedical Research on the subject’s behalf. However, the subject may participate in the main trial without participating in Future Biomedical Research.
3. Have a legal representative who is able to read, understand, and complete the vaccine report card.
4. Agree to provide study personnel with a primary telephone number as well as an alternate telephone number/email address for follow-up purpose.
5. Show no temperature ≥37.5˚C (oral) within 24 hours prior to vaccinations. If the subject does not meet this criterion, the Day 1 visit will be rescheduled for a time when this criterion can be met.
6. Must not yet have had coitarche and does not plan on becoming sexually active during the Day 1 through Month 7.
|
|
E.4 | Principal exclusion criteria |
1. Is concurrently enrolled in clinical studies of investigational agents
2. Has history of known prior vaccination with an HPV vaccine or plans to receive the HPV vaccine outside of the study.
3. Has receipt of inactivated vaccines within 14 days prior to enrollment or receipt of live virus vaccines within 28 days prior to enrollment. If the subject meets this criterion, the Day 1 visit will be rescheduled for a time when this criterion is not met.
4. Has history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
5. Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]).
6. Has received any immune globulin or blood derived products within the 6 months prior to the first injection, or plan to receive any through Month 7 of the study.
7. Has history of splenectomy or is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other auto immune condition.
8. Is receiving, or has received in the year prior to enrollment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monocolonal antibody therapies (including rituximab), intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere with the immune response.
With regard to systemic corticosteroids, a subject will be excluded if he is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrollment) received such therapy, or has received 2 or more courses of high dose corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to enrollment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study.
9. Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
10. Has history of recent (within the last 12 months) or ongoing alcohol or drug abuse. Alcohol and drug abusers are defined as those who drink or use drugs despite recurrent social, interpersonal, and legal problems as results of alcohol or drug use.
11. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the subject’s participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
12. Is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
13. Has a history of genital warts or a positive test for HPV.
14. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary immunogenicity endpoint will be seroconversion rate for the vaccine HPV types (6, 11, 16 and 18). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary endpoint includes cLIA geometric mean titers (GMTs) for the vaccine HPV type (6, 11, 16 and 18). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity and tolerability |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The subject participation portion of the overall trial ends when the last subject completes the last study - related phone call or visit, discontinues from the trial or is lost to follow -up (i.e., the subject is unable to be contacted by the investigator). For purposes of analysis and reporting, the overall trial ends when the Sponsor receives the last serology assay result or subject data from the last study-related phone call or visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |